Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Verastem ( (VSTM) ) just unveiled an announcement.
On October 23, 2025, Verastem announced preliminary data from its ongoing Phase 1/2a trial of VS-7375, an oral KRAS G12D inhibitor, showing promising safety and anti-tumor activity in patients with advanced KRAS G12D mutant solid tumors. The trial cleared initial monotherapy doses without dose-limiting toxicities and observed tumor reductions in most patients. Verastem has also started enrolling patients for a combination cohort with cetuximab and plans to report further updates in 2026.
The most recent analyst rating on (VSTM) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Verastem stock, see the VSTM Stock Forecast page.
Spark’s Take on VSTM Stock
According to Spark, TipRanks’ AI Analyst, VSTM is a Neutral.
Verastem’s overall stock score is primarily impacted by its weak financial performance, characterized by ongoing losses and negative equity. However, positive technical indicators and recent corporate events, such as the $75M private placement, provide some optimism for future growth. Valuation remains constrained by negative earnings, but strategic initiatives and product development efforts could drive improvements. The stock represents a speculative opportunity, with potential upside if financial health and operational efficiencies improve.
To see Spark’s full report on VSTM stock, click here.
More about Verastem
Verastem Oncology is a biopharmaceutical company focused on developing and commercializing new medicines for RAS/MAPK-pathway-driven cancers. The company markets AVMAPKI™ FAKZYNJA™ CO-PACK in the U.S. and is working on novel small molecule drugs targeting critical cancer signaling pathways, including RAF/MEK, FAK, and KRAS G12D inhibition.
Average Trading Volume: 2,535,645
Technical Sentiment Signal: Buy
Current Market Cap: $491.7M
Find detailed analytics on VSTM stock on TipRanks’ Stock Analysis page.